Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].

中证报中证网讯（王珞）5月7日，九芝堂复牌并撤销其他风险警示，日涨跌幅限制恢复10%，成功 实现"摘帽"。 根据此前公告，九芝堂因2023年内控审计报告被出具否定意见，被实施ST。九芝堂表示， 2024年以来，公司通过强化风险合规意识，加强内控管理，落实各项整改措施，开展内控质量提 升等工作，保证公司的内部控制有效运行，公司内部控制缺陷已经完成整改，2024年度内控审计 报告为标准无保留意见。 夯实基础 积极培育创新驱动力 2024年，在原材料价格上涨等因素影响下，中药企业经营普遍承压。九芝堂以产品为核心，在市场 较低迷的情况下依然保持了稳健的经营实力。 年报显示，公司2024年实现营业收入23.71亿元，归母净利润2.16亿元。报告期内，经营活动产生的 现金流1.99亿元，同比增长83.14%。 公司表示，2024年，公司坚定"推动公司实现高质量发展"的总体目标不动摇，努力克服客观因素带 来的不利影响，持续贯彻产销一体策略，坚持以产品为核心，维护重点品种平稳，培育潜力品种，挖潜 存量，推动增量，构建多元化的品种群梯队发展格局，积极打造业绩增长点。 传统业务领域，公司产品梯队逐步完善。在OTC领域，九芝堂拥有 ...